Pivotal readout
Arrowhead Reports Fiscal 2026 Results
Fiscal 2026 revenue fell to $450.8 million from $829.4 million, while Arrowhead's net loss widened to $724.2 million; year-end cash resources were $1.193 billion. REDEMPLO prescriptions grew and Arrowhead submitted an FDA supplemental application for severe hypertriglyceridemia after positive Phase 3 results; a potential U.S. launch is planned for the second quarter of 2027, subject to approval. Arrowhead reported interim ARO-DIMER-PA and ARO-MAPT data, completed enrollment in the Phase 3 YOSEMITE trial of zodasiran, and refinanced its credit facility.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.